## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.1% in lower entry zone (3.0-6.0%), top quartile (88th pct) cross-sectional ranking. Short-term MRS_5 (1.5%) confirms momentum alignment. Strong momentum (+2.1% 5-day acceleration). Outperforming sector by 4.1%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($73.87)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Westwood Holdings Group Inc. Invests $20.63 Million in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251215T140618 | Somewhat-Bullish | Relevance: 100%
- Westwood Holdings Group Inc. has acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC) valued at approximately $20.63 million, purchasing 282,420 shares in the second quarter. Other institutional investors also adjusted their holdings in Henry Schein, with several analysts offering price target adjustments and ratings from "buy" to "hold." The company's stock performance shows a market cap of $9.01 billion and a consensus "Hold" rating from analysts with an average price target of $76.92.

**2. Thompson Davis & CO. Inc. Buys Shares of 17,270 Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251214T120806 | Somewhat-Bullish | Relevance: 98%
- Thompson Davis & CO. Inc. initiated a new position in Henry Schein, Inc. (NASDAQ:HSIC) by purchasing 17,270 shares valued at approximately $1.26 million, making it their 26th largest holding. Henry Schein recently surpassed quarterly earnings and revenue expectations and provided strong FY2025 guidance. Despite several analysts raising price targets, the consensus rating for HSIC remains a "Hold" with an average price target of $76.92.

**3. Top 2 Health Care Stocks That May Keep You Up At Night In December**
- Source: Benzinga | 20251216T133242 | Somewhat-Bullish | Relevance: 92%
- This article identifies two healthcare stocks, Henry Schein (HSIC) and Avidity Biosciences (RNA), that might concern investors due to their overbought status indicated by a high Relative Strength Index (RSI). Avidity Biosciences recently missed analyst consensus on quarterly losses but beat sales estimates and announced a merger agreement with Novartis, while Henry Schein received an Overweight rating from Barclays. Investors are advised to consider momentum as a key trading criterion when evaluating these stocks.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +2.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.72 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.72 |
| Forward P/E | 14.6 |
| Current P/E | 15.7 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.0% to 4.1% (+2.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 88th percentile. MRS_5 at 1.5% confirms short-term momentum alignment. Outperforming sector by 4.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.08% (CS: 89) | Strong |
| RSI_14 | 67.0 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.040x | Above |
| vs SMA50 | 1.109x | Above |
| vs SMA200 | 1.112x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $77.05
- **Stop Loss:** $73.87 (4.1% risk)
- **Target:** $81.82 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 314
- **Position Value:** $24,193.70
- **Portfolio %:** 24.19%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*